SCHEMBL15613635

SCHEMBL15613635

Cc1ccc(COc2cc(F)cc(Oc3ccc(-c4nn(C(C)C)c(N)c4C#N)cc3)c2)cn1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 4/20 0.41
▸ SRC P12931 13/20 0.37
▸ ABL1 P00519 9/20 0.37
▸ SQOR Q9Y6N5 1/20 0.34
▸ PIK3CD O00329 4/20 0.34
▸ EGFR P00533 4/20 0.34
▸ HCK P08631 4/20 0.34
▸ KDR P35968 4/20 0.34
▸ PIK3CA P42336 4/20 0.34
▸ PIK3CB P42338 4/20 0.34
▸ MTOR P42345 4/20 0.34
▸ EPHB4 P54760 4/20 0.34
▸ PRKDC P78527 4/20 0.34
▸ PIK3CG P48736 3/20 0.34
▸ PI4KB Q9UBF8 2/20 0.34
▸ GRM2 Q14416 1/20 0.33
▸ GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15613741 0.92 BTK (0.48) BTKSRCABL1SQORPIK3CD
SCHEMBL15613584 0.90 BTK (0.38) BTKSRCABL1SQORPIK3CD
SCHEMBL15613739 0.84 BTK (0.35) BTKSRCABL1PIK3CDEGFR
SCHEMBL15613686 0.83 BTK (0.47) BTKSRCABL1SQORGRM2
SCHEMBL15613627 0.81 SRC (0.59) SRCABL1PIK3CDEGFRHCK
SCHEMBL19490550 0.79 SRC (0.48) SRCABL1PIK3CDEGFRHCK
SCHEMBL15613693 0.78 BTK (0.49) BTKSRCSQORGRM2
SCHEMBL15613592 0.76 BTK (0.35) BTKSRCABL1GRM2
SCHEMBL15613694 0.75 BTK (0.47) BTKSQORGRM2
SCHEMBL15614922 0.75 BTK (0.37) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK BTK 10/4885SRC 2/4885ABL1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback